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Summary Twenty patients with malignant head and neck tumours were imaged with 9Tcm-labelled hexa-
methylpropylene amine oxime (HMPAO), a radiopharmaceutical generally used for blood flow studies. Before
radiotherapy (RT), 93% of the tumours could be detected with single photon emission computed tomography
(SPECT) and 45% with planar imaging. Whole tumour-to-background "TcmHMPAO uptake ratios ranged
from 3.6 to 1.0 (mean 1.7 0.6) in untreated tumours. There was a good correlation between tumour volume
and uptake (r = 0.69, P= 0.002). Sixteen patients were reimaged during or shortly after radical RT.
9TcmHMPAO uptake was significantly lower after treatment (mean uptake ratio 1.2 ± 0.3, P<0.001).
However, RT associated changes in 9TcmHMPAO uptake were in agreement with the clinical response in only
63% of the studies. This study indicates that 9TcmHMPAO SPECT imaging can be used for pretherapeutic
localisation ofhead and neck tumours. Although most tumours show a decrease in uptake after irradiation the
poor association with tumour regression does not allow for reliable assessment of treatment response.
Since tumour blood flow may be a crucial determinant of the
effect of chemo- and radiotherapy, there is a great need for
rapid and, preferably, non-invasive methods to assess tumour
perfusion. Positron emission tomography (PET) provides the
most accurate means of quantitative measurement of blood
flow but the costs of positron imaging prohibits its wide-
spread use (Kuhl et al., 1988). In contrast, single photon
emission tomography (SPECT) with 9Tcm-labelled radiophar-
maceuticals, if feasible, could be appropriate for clinical
tumour blood flow studies. However, such methods have not
been validated consistently for general purpose imaging of
neoplasms to study effects of therapeutic interventions (Vau-
pel et al., 1989).
Initial experience with 'Tcm hexamethylpropylene amine
oxime (HMPAO) in animal (Hammersley et al., 1987) and
human tumours (Tait et al., 1987) holds the promise of a
tracer for measurement of tumour blood flow. 9TcmHMPAO
is lipophilic, has a high first pass extraction and is retained
sufficiently for imaging at least in brain tissue; these circum-
stances render 9TcmHMPAO the useful tracer for SPECT
studies of cerebral blood flow (Andersen et al., 1988). In
human gliomas, the relationship between regional blood flow
and 9TcmHMPAO uptake has been verified by comparing
9TcmHMPAO SPECT and C[150]02 PET images (Langen et
al., 1987).
Uptakes of 9TCmHMPAO and 86Rb correlate positively in
untreated tumours and normal tissues in mice (Hammersley
et al., 1987) after propranolol treatment and pentobarbital
anaesthesia. Fujii et al. (1990) found a good correlation
between 'TcmHMPAO uptake and radionuclide angiography
during the arterial phase and with 201TI perfusion imaging in
a study of non-cerebral human tumours; r67Ga]citrate and
9TcmHMPAO images did not coincide. Recently, lung tu-
mours (Oshima et al., 1989; Rowell et al., 1989) and sarco-
mas (Sinnett et al., 1990) have also been imaged with
9TcmHMPAO.
The present knowledge favours the concept that 'Tcm
HMPAO uptake does depict perfusion also in other than
brain tumours. However, an important question must be
asked: can 99TcmHMPAO be used for measurement of chan-
ges in tumour perfusion caused by cancer therapy and, more
specifically, can these changes be related to response to treat-
ment? The present study was designed in an attempt to
answer these questions by studying 9TcmHMPAO uptake of
malignant head and neck tumours both before and after
megavoltage radiotherapy (RT).
Patients and methods
Twenty patients (nine male, 11 female) admitted to the
Turku University Central Hospital between May 1987 and
June 1990 were enrolled into the study. They were referred
for RT because of head and neck cancer. The mean age was
68 years (range: 36-89). Seventeen patients had squamous
cell cancer, one lymphoepithelial cancer, one soft tissue sar-
coma and one Merkel cell carcinoma (Table I). Clinical
staging included naso-endoscopy, microlaryngoscopy, chest
X-ray and computed tomography (CT). All tumours were
clearly detectable by one or several of these diagnostic proce-
dures and the minimum diameter at least in one direction
Table I Patient and tumour characteristics
Patient
no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Age/Sex
69/F
36/F
72/F
85/F
62/M
59/M
86/M
38/M
73/M
71/F
79/F
89/F
53/M
72/F
82/F
59/M
73/F
Primary
tumour
Hypopharynx
Maxilla
Hypopharynx
Lower gum
Larynx
Tongue
Unknown
Floor of
mouth
Larynx
Oesophagus
Nose
Lower gum
Larynx
Larynx
Tongue
Larynx
Skin of chin
58/M Larynx
72/M Nasopharynx
80/F Lower gum
Stage by
UICC
T4NO
T2NO
T4N3
T3NO
T2N1
T2NI
TxN3
T2N2
T4NO
T4NX
TINO
T2NO
T2NO
T2N1
T4NI
T2N3
T2NO
T2NO
T4N2
T2N1
Histology
sCC
sarcoma
sCC
SCC
SCC
sCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
Merkel
carcinoma
SCC
LC
SCC
Grade
WD
PD
MD
WD
WD
WD
MD
MD
MD
MD
PD
PD
MD
MD
WD
MD
PD
MD
PD
WD
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UICC, international union against cancer; SCC, squamous cell
cancer; LC, lymphoepithelial cancer; WD, well differentiated; MD,
moderately differentiated; PD, poorly differentiated.
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was 2 cm. Informed consent was obtained from each patient.
The first study was made before any radio- or chemo-
therapy. The imaging device was a dual-detector Siemens
Rota Mk. I (Siemens Gammasonics, Inc., Illinois, USA)
camera equipped with low energy high resolution collimators.
Imaging was started immediately after an intravenous bolus
injection of 750 MBq 'Tc"HMPAO (Ceretec, Amersham
International, Amersham, UK) and dynamic scans (frame
rate 10 s/image, total 12 frames) were obtained in the ap-pro-
jection, followed in few minutes by a planar blood-pool
image. Between 10-15 min from the injection, planar views
of 400,000 counts/image were obtained in anterior, posterior
and lateral projections. Thereafter, 360 degree acquisitions
(60 views, 64 x 64 pixels, 20 s per view) were collected and
tomographic images of 64 x 64 pixels were reconstructed in
the transaxial, coronal and sagittal planes using a Shepp-
Logan backprojection filter and SPETS-11 software (Nuclear
Diagnostics Ab). Depending on the radius of rotation and
the selected filter, the spatial resolution of the SPECT system
varied between 16 and 20 mm. Attenuation correction was
not used.
Planar images and transaxial, coronal and sagittal sections
were reviewed first visually to select planes for further
analysis. Tracer uptake within the tumour was then deter-
mined by superimposition of 2-4 regions of interest (ROI) in
the selected transaxial and/or coronal plane intersecting
through the centre of the tumour mass. The first ROI encom-
passed the whole tumour; 1-3 smaller ROTs with a pixel size
of 3 x 3 were selected from the central and peripheral parts
of the tumour to define maximum/minimum values for tracer
uptake (cf. Rowell et al., 1989). A control ROI of identical
shape was chosen from the contralateral side ofneck tissue in
the same plane, carefully excluding submandibular, parotid
and thyroid glands. By recording the average count rates in
each of these ROTs, tumour-to-background (i.e. neck tissue)
uptake ratios were determined.
Tumour volumes were calculated by measuring two or
three perpendicular diameters clinically or from CT scans, as
described elsewhere (Rowell et al., 1989; Sinnett et al., 1990).
The relationship between tumour volume and 'TcKHMPAO
uptake (and their logarithmic values) was evaluated by linear
regression curve fitting. Correlation curves were plotted sep-
arately for whole, peripheral and central uptake ratios. One-
way analysis of variance was used for comparisons of uptake
ratios with tumour grade as the grouping factor.
Sixteen patients were studied during or after a course of
megavoltage radiation treatment. The dose and fractionation
were conventional (2 Gy/day, five fractions weekly). Clin-
ically, response to treatment was recorded as regression, if
tumour volume had decreased > 50% at the time of the
second study; other tumours were regarded as non-
responsive. Pre- and post-irradiation ratios of tracer uptake
Figure 1 'TcmHMPAO images of patients with head and neck tumours: a, transaxial SPECT image of nasopharyngeal cancer
(arrow; patient 19). An increased 99Tcm-activity can be seen in the parotid glands and cerebellum. b, sagittal SPECT image of
Merkel cell carcinoma (patient 17) in the top of chin. This tumour had a very high 9Tc"HMPAO uptake (central uptake ratio 4.6,
peripheral uptake ratio 3.6). c, coronal SPECT image of larynx cancer (patient 9) which shows clearly the site of tumour (arrow)
cranial and left from the tracheostomy (arrowhead); salivary glands above the tumour are also seen. d, blood-pool image of neck
metastasis from laryngeal cancer (patient 18) 5 min after 9TcmHMPAO injection shows tracer accumulation in tumour area.
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were compared by the paired two-tailed t-test. For groupwise
comparisons of tumour response and 'TcmHMPAO uptake,
the chi-square test with Yates correction was used.
Results
Visual inspection
Figure la-d shows examples of pretreatment 'TcmHMPAO
images. In total, 28 tumours in 20 patients were evaluated
visually. The results of the pre- and postradiotherapeutic
studies are shown in Table II. SPECT enhanced considerably
the tumour detection rate: 19/20 patients had pathological
findings consistent with tumour uptake in 26/28 tumours
(93%) in SPECT, whereas planar images were positive in
only 11 patients (9/20 tumours, 45%). There were only two
tumours that were not seen with SPECT: patient 11 had a
recurrent squamous cell cancer of the upper gum and lip in a
previously operated and irradiated area; the size of this
superficial tumour was 1.5 x 2 cm. Also, the supraglottic
laryngeal primary tumour of patient 16 (size: 3 x 2 cm) was
difficult to discern from the adjoining large neck metastasis
(size: 6.5 x 5.5 cm) and was therefore interpreted as non-
detectable.
No tumour showed decreased 'TcmHMPAO uptake
(photopenic area) as compared to the surrounding neck tis-
sue, although increased uptake was observed in the parotid,
submandibular and thyroid glands. Often the central tumour
regions had a more intensive uptake than the peripheral
parts. In contrast, circular uptake was seen in three lymph
node metastases (Figure 4c), one of which was missed by
planar imaging.
Table III lists relationships between the effectiveness of the
different phases of the study and the pathologic grade of the
tumours. There were no major differences between the three
groups although the dynamic and blood-pool images tended
to be normal in well differentiated tumours (Table III).
99Tc'HMPAO uptake ratios
The volume and uptake of 99TcmHMPAO of 20 tumours in
17 patients were calculated for quantitative analysis (Table
IV). The mean total tumour uptake was 1.7 ± 0.6 and the
mean central uptake, 1.8 ± 0.8 (N.S.). There were only two
patients who had clear difference between central and
peripheral uptake (patients 7 and 17; see Figures 1 and 4).
Although there was a great overlap between the uptake ratios
of individual tumours (F = 0.55, P = 0.59; Figure 2), the
Table II % Of head and neck tumours seen by 'TcmHMPAO
SPECT
Before After
RT RTb
Dynamic phase 19 13
Blood-pool image 40 30
Planar images 45 29
Tomographic images 93 63
RT, radiotherapy; 128 tumours in 20 patients; b20 tumours in 16
patients.
Table III % Ofprimary head and neck tumours with a pathologic
appearance on 9TcmHMPAO SPECT by histologic grade
WD MD PD Total
(n =6) (n = 9) (n= 5) (n =20)
Dynamic phase 0 33 20 20
Blood-pool image 20a 50a 60 45
Planar images 33b 55 40b 45c
Tomographic images 83b 100 80 90"
WD, well differentiated; MD, moderately differentiated; PD, poorly
differentiated; aOne study not evaluable; 'One additional patient had a
pathologic finding in a metastatic tumour; C55% ifmetastatic tumours
included; d95% if metastatic tumours included.
Table IV Tumour-to-neck tissue 9TcmHMPAO SPECTuptake ratios
of 20 patients with head and neck tumour before and after radiation
treatment (RT)
99Tcm-uptake ratiob
Time
Tumour Dose ofRT between
Patient volumea Before After given before studies
no. (cm3) RT RT 2nd study (weeks)
1 79 NC NCc 22Gy 2
2 65 1.8 1.2 64Gy 7
3 34 1.8 1.6 47Gy 5
4 12 1.8 1.0 66Gy 10
5 22 1.1 1.2 32Gy 4
6 6 1.3 1.0 30Gy 6
7 113 2.4 2.0 58Gy 10
8 6 NC ND
9 25 1.3 ND
10 48 1.7 1.0 34Gy 4
11 3 1.0 ND
12 3 1.4 1.0 39Gy 5
'13 6 1.5 1.2 60Gy 6
14 4 NC NC 58Gy 8
15 31 1.6 1.2 53Gy 7
16 112 1.6 NO' 52Gy 7
4 1.6 NC
17 22 3.6 ND
18 87 1.9 1.3 50Gy 7
19 24 1.8 1.3 60Gy 7
34 2.1 1.2
20 8 1.3 1.2 47Gy 6
4 1.1 1.1
NC, not calculated; ND, 2nd study not done; aBefore RT. In three
patients (16, 19 and 20) volume and uptake ratio of primary and
secondarytumourshasbeencalculated separately;bCalculatedfrom the
wholetumour;cVisuallyuptakedecreased;dVisuallyuptakeunchanged.
WD MD PD
Histologic grade
Figure 2 Pretreatment 99TcmHMPAO uptake ratios (± one
standard deviation) of 20 head and neck tumours according to
histologic grade. WD, well differentiated; MD, moderately
differentiated; PD, poorly differentiated.
highest ratios were detected in the most poorly differentiated
tumours. The uptake of tracer into tumours which were seen
in the dynamic scans was 2.3 ± 1.0 (n =4, N.S.) and the
uptake of tumours which were detected in the blood-pool
image was 2.0 ± 0.7 (n = 9, N.S.). Among the 17 patients
with a squamous cell cancer and one lympho-epithelioma
(patient 19) there was a good correlation between the log
value of tumour volume and 9TcmHMPAO whole tumour
uptake ratio (r = 0.69, P = 0.002; Figure 3). The same was
true for log value of tumour volume and peripheral uptake
ratio (r = 0.65, P = 0.003) but not for central tumour uptake
(r = 0.44, P = 0.07).
Radiation effect
Sixteen patients underwent a second study during or shortly
after radiation treatment. The mean RT dose at the time of
imaging was 48 ± 13 Gy and the mean time elapsed from the738 H. MINN et al.
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Figure 3 Whole tumour:neck tissue 99TcmHMPAO uptake ratio
vs tumour volume of 18 patients with head and neck cancer
(r = 0.69, P= 0.002).
start of RT was 6 ± 2 weeks (see Table IV). Visually, 12
(75%) patients had a decrease in 'TcmHMPAO uptake as
compared to the first study (Table V). After irradiation,
whole-tumour and central uptake ratios were identical (mean
1.2 ± 0.3), which implies that the tracer was taken up
relatively homogenously. The difference between pre- and
post-treatment whole-tumour uptake ratios was significant
(1.7 ± 0.6 vs 1.2 + 0.3; P<0.001). In one study (patient 7)
the abnormal dynamic study became normal after RT but
the reverse was true for another study (patient 18). In the
two pretreatment studies which showed a circular uptake of
'TcmHMPAO by the tumour, tracer distribution after RT
lost the circular pattern as a response to irradiation (Figure
4c-d); in one patient a tumour ring pattern appeared after
treatment (patient 20).
There was no correlation between the decrement of uptake
and regression of tumour volume (n = 11, r = 0.31, P = 0.35).
In line with this, clinical response and changes in
'TcmHMPAO uptake agreed in only 10/16 (63%) of the
cases (chi-square = 0.33, P = 0.56; Table V).
Discussion
Tumour blood flow rate is determined by the arteriovenous
pressure difference and by viscous and geometric resistances
of the vascular network in the proximity of or within neo-
plastic tissue (Jain, 1988). Although quantitative data on the
variables that govern blood flow is scarce in human tumours
(Vaupel et al., 1989), there is evidence that vascular density
and morphometry can, to some extent, predict the outcome
of RT (Revesz et al., 1989). However, these methods do not
measure perfusion directly, which is essential for evaluation
of drug delivery and the oxygen status of tumours. Assess-
ment of blood flow non-invasively, e.g., by radionuclide
imaging would certainly be clinically more appealing than
procedures which require biopsy of tumour tissue.
'TcmHMPAO has been studied as a tumour imaging agent
.dx
Figure 4 Transaxial 99TcmHMPAO SPECT images ofpatients with squamous cell cancer of head and neck. Tumour in lower gum
before (a; arrow) and after b, treatment (patient 4). A large lymph node metastasis in neck before c, and after d, treatment (patient
7). Circular uptake of the tracer in the tumour is evident in the pretreatment images (whole tumour uptake ratio 2.4, peripheral
uptake ratio 3:1, central uptake ratio 1.3).9TCmHMPAO IMAGING OF HEAD AND NECK TUMOURS 739
Table V Relationship between response to radiation treatment and
changes in 'TcmHMPAO SPECT uptake in 16 patients with head and
neck cancer (expressed as number of patients)
9TTc'HMPAO uptake
Tumour response No change/increased Decreased
No change 3 5
Regression 1 7
both in connection with (Babich et al., 1988; Rowell et al.,
1990) and without (Tait et al., 1987; Fujii et al., 1990; Irvine
et al., 1990) therapeutic interventions. Obviously, this radio-
pharmaceutical seems to be suitable for detection of very
different types of tumours and compares favourable with,
e.g., 67Ga (Fujii et al., 1990). Further, models for quanti-
fication of tumour blood flow with 9TcmHMPAO have been
developed (Rowell et al., 1990).
In our study, the high rate of detection of head and neck
tumours confirms the applicability of 'TcmHMPAO for
imaging of neoplastic disease. We found increased 'Tcm
HMPAO uptake in both primary and secondary squamous
cell cancer as well as in one soft tissue sarcoma and a Merkel
cell carcinoma; the only patient with no abnormal findings in
'TcmHMPAO SPECT (patient 11) had been treated pre-
viously by surgical excision and RT. The small size of this
relapsing cancer was probably the main reason for the
unchanged uptake. Further, the blood circulation of the
tumour bed was affected by irradiation.
In contrast to what has been found for lung cancer
(Rowell et al., 1989) and cerebral gliomas (Irvine et al.,
1990), no head and neck tumours in this study exhibited less
uptake of 'Tc&HMPAO than the surrounding tissue. Higher
uptake ratios in neck tumours as compared to pulmonary or
cerebral malignancies may result from the low blood flow in
skeletal neck muscles (Vaupel et al., 1989). Clearly, the good
contrast caused by low uptake in normal neck muscle
enhances the tumour imaging potential of 'TcmHMPAO
SPECT in the head and neck region.
The positive correlation between 'TcmHMPAO uptake
and whole tumour volume may indicate that high blood flow
is maintained in the majority of head and neck tumours at
the time they become clinically manifest. High 'TcmHMPAO
uptake does not, however, necessarily imply good overall
oxygenation, since hypoxic tumour cells cannot be detected
with certainty by perfusion imaging with radionuclide tech-
niques (Chapman, 1991). Rather, high 'Tc&HMPAO uptake
may be associated with increased tumour metabolism which,
in turn, is related to poor prognosis, as shown by PET-brain
studies (DiChiro, 1987). In line with this, a high 'Tcm
HMPAO uptake has been shown to constitute an adverse
prognostic factor in patients with cerebral gliomas (Irvine et
al., 1990).
In lung tumours (Rowell et al., 1989) and soft tissue
sarcomas (Sinnett et al., 1990), a greater uptake in peripheral
rather than central parts of the tumour has been observed. In
contrast, most of the tumours in our study showed uniform
tracer distribution and a ringlike appearance of 'Tcm
HMPAO uptake was seen only in two pre- and one post-
treatment images. The poor correlation between central tu-
mour uptake and volume in the present study suggests that
necrotic areas were too small to be detected by 'Tcm
HMPAO SPECT; as the disease proceeds and necrotic areas
within tumour enlarge it may be expected that the correlation
turns negative (Rowell et al., 1989). The findings in the
largest tumour in our series favours this concept (patient 7;
see Figure 4c). Thus, the discrepancy between our observa-
tions and those related to sarcomas and lung tumours may
largely be explained by more advanced disease in the latter
group; specifically, the size of the tumours in the present
study was notably smaller than that of the lung tumours in
the study of Rowell et al. (1989).
In 75% of the patients that were studied both before and
after treatment, RT impaired 9TcmHMPAO uptake in the
tumour. Radiation induced also changes in the uptake pat-
tern: disappearance of poorly perfused centres and decreased
tracer flow in tumour region were seen in the dynamic and
blood-pool images. Generally speaking, the distribution of
the tracer within the tumour tissue became more diffuse and
homogenous after RT. In four patients the second 'Tcm
HMPAO scan was considered to be normal. However, reduc-
tion of uptake was not necessarily related to clinical tumour
regression: some tumours that responded poorly to irradia-
tion showed less tracer uptake in follow-up images (see Table
V).
Babich et al. (1988) monitored patients with glioma and
with cerebral metastases from oat cell carcinoma of the
bronchus with 'TcmHMPAO imaging during RT. They
found that the tumour-to-contralateral brain tissue uptake
ratios tended to normalise in responding tumours. Langen et
al. (1989) reported that ACNU chemotherapy did not change
'TcmHMPAO uptake in two patients with gliomas, while no
more than 16 Gy irradiation decreased the tumour-to-cere-
bellum uptake ratio to normal in a patient with recurrent
glioblastoma. It has even been suggested that 9TcmHMPAO
SPECT of brain tumours may be ofvalue in the follow-up of
patients being treated (Biersack et al., 1991). This statement
is not supported by our observations with head and neck
tumours. However, the overall low number of patients stud-
ied thus far does not allow definitive conclusions on the
applicability of'TcmHMPAO SPECT for measuring therapy
response.
In this study we did not correlate 'TcmHMPAO uptake to
other methods that assess blood flow in tumours, and it may
be premature to claim that increased 99TcmHMPAO uptake
in head and neck tumours would be solely associated with
increased blood flow. The blood flow rate in lymphomas is,
on average, higher than that of squamous cell cancer (Man-
tylii, 1979) and 'TcmHMPAO uptake would, consequently,
be expected to be high in these non-epithelial tumours. We
have also studied 16 patients with lymphoma and have found
that over 50% of the diseased nodes remained undetectable
in 'TcmHMPAO SPECT (unpublished data). It appears that
HMPAO uptake in tumours depends also on other factors
than blood flow, e.g., histology and mechanism of binding in
tumour cells (Biersack et al., 1991).
In healthy subjects, there is significant uptake of the tracer
in the hepatocytes, and extraction takes place via the
hepatobiliary route (Sharp et al., 1986). This is a drawback
for imaging of intra-abdominal tumours, and other radio-
pharmaceuticals than 'TcmHMPAO should be sought for if
perfusion studies of the infradiaphragmatic areas are made.
In the head and neck region, uptake in the salivary and
thyroid glands is often of the same order as that of tumours.
Our experience shows, however, that tumour tissue can
readily be distinguished from these benign 'hot' areas, and
the salivary or thyroid glands do not hamper visual inter-
pretation of tomographic 99TcmHMPAO images. Further,
SPECT is essential for the evaluation of 99TcmHMPAO up-
take in head and neck region, and we would discourage
planar imaging of these tumours with 99TcmHMPAO (cf.
Table II). To facilitate tumour detection, all three views, i.e.,
transaxial, sagittal and coronal, are necessary.
In summary, squamous cell cancer of the head and neck
region can well be imaged with 9TcmHMPAO and SPECT;
also other neoplasias originating in this area are detectable,
as shown by positive images of soft tissue sarcoma and
Merkel cell carcinoma. Typically, RT induces a decrement in
99TcmHMPAO uptake which, however, is not always associ-
ated with tumour response (Table V). It is unclear how the
decreased uptake is related to changes in tumour perfusion
and oxygenation and we cannot recommend 'TcmHMPAO
imaging for assessment of response to RT in patients with
head and neck tumours. Also, since the mechanism by which
this lipophilic tracer is trapped in tumours is not completely
understood, further investigations are warranted before 'Tcm
HMPAO may be used as a radiopharmaceutical for tumour
blood flow studies of head and neck region.
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